<DOC>
	<DOCNO>NCT01884155</DOCNO>
	<brief_summary>This open label trial conduct investigate efficacy safety allogeneic umbilical cord blood ( UCB ) therapy patient stroke .</brief_summary>
	<brief_title>Allogeneic Umbilical Cord Blood Therapy Stroke</brief_title>
	<detailed_description>Stroke one common etiologies cause disability develop country . There remain proven treatment except tissue plasminogen activator currently . Based promising result cell therapy animal stroke model , effort apply cell therapy patient stroke make . UCB posse various stem progenitor cell know secrete neurotrophic factor repair injured brain . This clinical research aim determine safety efficacy allogeneic UCB stroke .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>Ischemic hemorrhagic stroke Onset duration 12 month Hemisphere lesion except brain stem cerebellar lesion National Institute Health Stroke Scale : 10 15 Possibility hypersensitivity drug use study Uncontrolled hypertension cardiovascualr diseases Malignant cancer Renal hepatic dysfunction ( Consultation specialist nephrology gastroenterology case renal hepatic dysfunction ) Severe pulmonary dysfunction Traumatic brain injury Lack match UCB</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>